Tennessee Clinical Trials Report — April 2026

For Tennesseans considering participation in medical research, April 2026 presents a critical window of opportunity, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, 121 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 18 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, heart conditions, and other specific ailments are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Ewing sarcoma
• Metastatic breast cancer
• Advanced solid tumors
• Dry eye disease
• Heart failure
• Long COVID
• Acute myeloid leukemia
• Acute kidney injury
• Breast cancer
• Advanced breast cancer

New Horizons in Research: Major Trials Launching Across Tennessee

This month brings several high-profile new trials to Tennessee, including significant Phase 2 and 3 studies from major pharmaceutical companies and leading research institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to advanced cancers and conditions affecting childhood cancer survivors.

Tennessee saw 15 new trials open this month, which is a decrease from the 25 trials that launched in March 2026. Despite this dip, the quality and potential impact of the new studies remain high, with notable sponsors driving forward important research.

• Novo Nordisk A/S is launching NCT07533175, "AMAZE 2," a Phase 3 study investigating how well the medicine NNC0487-0111 helps people with excess body weight and Type 2 diabetes lose weight. This large trial aims to enroll 630 participants to evaluate the safety and effectiveness of this weekly injectable treatment.
• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants.
• Priovant Therapeutics, Inc. is conducting NCT07532603, a Phase 2/3 study of brepocitinib in adults with lichen planopilaris, designed for 342 participants.
• Vanderbilt University Medical Center is leading two significant studies:
  • NCT07536984, "Examination of Personalized SpO2 Targets," a large study involving 3,000 participants to understand optimal oxygen saturation targets for critically ill adults on mechanical ventilation.
  • NCT07529691, a "Survey on Physical Activity and Quality of Life in Fibromuscular Dysplasia," an observational study seeking 2,000 participants to better understand this arterial disease, which predominantly impacts women.
• St. Jude Children's Research Hospital is sponsoring NCT07531498, "Muscle Aging Phenotypes in Childhood Cancer Survivors," an observational study involving 533 participants to characterize the biological mechanisms driving premature declines in muscle health among survivors.
• Mead Johnson Nutrition is sponsoring NCT07513506, an "Extensively Hydrolyzed Formula Growth Monitoring Study," comparing an investigational infant formula against a currently marketed one, with 214 participants.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. This month, 5 of the 15 new trials are actively seeking healthy volunteers. Statewide, a total of 139 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research without having a particular diagnosis.

Participation in clinical trials is also open to a wide range of demographics. Of the new trials launched this month, 13 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 4 new trials are open to children. There is also one new study specifically for female participants and one for male participants, addressing unique health needs within these groups.

Tennessee's Research Footprint: Where to Find Trials

Tennessee continues to be a hub for medical research, with 1,912 clinical trials currently recruiting across 53 cities and 1,013 research sites. This broad distribution ensures that opportunities are accessible to residents across the state, not just in major metropolitan areas.

This month's new research initiatives are primarily concentrated in Tennessee's largest cities, offering convenient access for many residents. New trials opened in:

• Nashville (7 new trials)
• Memphis (6 new trials)
• Chattanooga (1 new trial)
• Smyrna (1 new trial)

The types of interventions being studied are varied, with drug trials leading the way, accounting for 6 of the new trials. Other types of studies, including behavioral interventions, device studies, dietary supplements, and radiation studies, also opened this month, reflecting a diverse approach to medical advancement.

Leading academic institutions like Vanderbilt University Medical Center and St. Jude Children's Research Hospital continue to play a vital role in Tennessee's research ecosystem, sponsoring 3 new trials each this month. Industry sponsors, including Novo Nordisk A/S, Incyte Corporation, Mead Johnson Nutrition, Priovant Therapeutics, Inc., and Halda Therapeutics OpCo, Inc., are also driving significant research efforts, accounting for 7 of the new studies this month.

As we move further into spring, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Tennessee.